Source: Healio News
The last few years have yielded “incredible numbers of new drugs approved and under development” in multiple myeloma, Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.
This includes the FDA approval of idecabtagene vicleucel (Abecma; Bristol Myers Squibb, bluebird bio), the first CAR T-cell therapy for multiple myeloma, based on findings from the KarMMa trial. At the virtual ASCO Annual Meeting, updated data on another CAR T-cell therapy, ciltacabtagene autoleucel (Janssen, Legend Biotech) was presented from the